<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195806</url>
  </required_header>
  <id_info>
    <org_study_id>M03-648</org_study_id>
    <nct_id>NCT00195806</nct_id>
  </id_info>
  <brief_title>Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine</brief_title>
  <official_title>Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-Label, Long-Term Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if long-term treatment, up to 1 year, with Depakote
      ER is safe in the reduction of occurrence of migraine headaches in adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of migraine headache days</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study drug exposure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral/cognitive assessments</measure>
  </secondary_outcome>
  <enrollment>315</enrollment>
  <condition>Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>divalproex sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject and subject's legal representative have voluntarily signed and dated an
             IRB-approved informed assent form and an IRB-approved informed consent form,
             respectively, before any study-specific procedures or tests are performed;

          -  Subject is male, or a non-pregnant, non-lactating female;

          -  Subject is between 12 and 17 years of age, inclusive, at the Screening Visit;

          -  Subject weighs at least 77 lbs. (i.e., 35 kg);

          -  Subject currently has diagnosis of migraine headaches consistent with International
             Headache Society (IHS) criteria;

          -  Subject is judged to be in generally good health based on the results of a medical
             history, physical examination, 12-lead electrocardiogram (ECG), and laboratory
             profile; and

          -  In the investigator's opinion, the subject will benefit from Depakote ER for migraine
             prophylaxis.

        Exclusion Criteria:

          -  History of allergic reaction or significant sensitivity to valproate or similar drugs;

          -  History of noncompliance with medication or medical instructions;

          -  Recent (previous 6 months) history of drug and/or alcohol abuse or has a positive
             urine drug screen, at the Screening Visit, for drugs of abuse (e.g., amphetamines,
             barbiturates, benzodiazepines, cocaine, opiates, and phencyclidine [PCP]);

          -  Female, of childbearing potential, and not using an effective method of birth control
             (e.g., total sexual abstinence or contraceptives) as judged by the investigator.

          -  Use of the following medication classes or any specific drug listed below:

               -  anti-depressants, other antiepileptic drugs (AEDs)

               -  aspirin and/or aspirin-containing products

               -  chronic use of systemic corticosteroids, clonazepam,diazepam, erythromycin,
                  ethosuximide, pemoline, phenobarbital,rifampin,tolbutamide, zidovudine

               -  anticoagulant drug therapy;

          -  Any serious medical or psychiatric disorder(s), including epilepsy and obesity, that
             may confound the interpretation of the results from this study;

          -  Central nervous system (CNS) neoplasm, CNS infection, demyelinating disease,
             degenerative neurological disease, or any progressive CNS disease;

          -  History of encephalopathy, hepatitis, pancreatitis, or urea-cycle disorder or any
             underlying condition/disease, which might interfere with study drug absorption or
             completion of study drug therapy evaluation throughout the duration of the trial;

          -  Screening laboratory results indicate the presence of Hepatitis B surface antigen
             (HBsAg), or Hepatitis C antibody or known history of any positive test result for HIV;

          -  Screening laboratory results indicate:

               1. Platelet count =/&lt; 100,000/uL

               2. ALT or AST =/&gt; 2 times Upper Limit of Normal (ULN);

          -  Receipt of an investigational drug within 30 days prior to study drug administration
             or scheduled to receive any other investigational drug anytime during the study;

          -  Participation in a prior Depakote ER migraine study (M02-488 or M02-554); or if for
             any reason, subject is considered by the investigator to be an unsuitable candidate to
             receive Depakote or to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information 800-633-9110</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Medical Information - Abbott</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 30, 2007</last_update_submitted>
  <last_update_submitted_qc>August 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2007</last_update_posted>
  <keyword>Migraine</keyword>
  <keyword>Depakote ER</keyword>
  <keyword>Divalproex sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

